dm199
Recombinant proteinexperimental
Clinical trial activity
8 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Dec 1, 2011 (NCT01558245)
Timeline
Indications
Mechanism of action
- Kallikrein 1INHIBITOR
KLK1 inhibitor
- Kallikrein 1Supplementation
KLK1 supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- dm199
- tissue kallikrein
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06875141 | N/A | Nov 1, 2024 | DiaMedica USA Inc. |
| NCT05065216 | Phase 2/Phase 3 (Phase 3) | Sep 24, 2021 | DiaMedica USA Inc. |
| NCT04123613 | Phase 2 | Oct 31, 2019 | DiaMedica USA Inc. |
| NCT03795389 | Phase 1 | Feb 12, 2019 | DiaMedica USA Inc. |
| NCT03290560 | Phase 2 | Jan 19, 2018 | DiaMedica USA Inc., Melbourne Health |
| NCT02868996 | Phase 1 | Sep 1, 2016 | DiaMedica USA Inc., Novotech |
| NCT01845064 | Phase 1/Phase 2 (Phase 2) | Apr 1, 2013 | DiaMedica USA Inc., Pharmaceutical Research Associates, Inc. (PRA) |
| NCT01558245 | Phase 2 | Dec 1, 2011 | Jinlin University, Nanjing University |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DiaMedica USA Inc. | For profit | 7 | 7 | 4 | 2013 |
| Jinlin University | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Melbourne Health | Academic/Hospital | 1 | 0 | 1 | 2018 |
| Nanjing University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Novotech | For profit | 1 | 0 | 1 | 2016 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2013 |
6 organizations
Page 1 / 1